This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: M33.2 (polymyositis) | Special Copayment Reduction: V137 (rare disease) |
| B. Synonyms | — |
| C. Adult onset | Likelihood of first onset in adulthood: very high — polymyositis is by definition an inflammatory myopathy that develops in adults (mainly in their 40s~60s). Childhood polymyositis is very rare (less than about 10% of pediatric IIM), and adult onset is overwhelmingly predominant. According to recent redefinitions, a considerable proportion of cases previously classified as 'polymyositis' are reclassified as immune-mediated necrotizing myopathy (IMNM) or antisynthetase syndrome, and true polymyositis is re-estimated to account for about 20~30% of adult idiopathic inflammatory myopathies. Female:male = about 2:1. |
| 1. History | 1863 first description of myositis by Wagner → 1916 separate description of polymyositis and dermatomyositis → 1975 Bohan-Peter classification criteria — subtype of PM without skin findings established → 2004 concept of immune-mediated necrotizing myopathy (IMNM) separated → 2017 EULAR/ACR criteria: difficulty classifying PM recognized due to absence of specific items → 2022 ENMC redefinition of the scope of PM. |
| 2. Causes | Direct attack on muscle fibers by CD8+ cytotoxic T cells is the core mechanism. Genetic predisposition (HLA-DR3, HLA-DR5, HLA-DQ genotypes), association with antisynthetase syndrome (MSAs such as anti-Jo-1), overlap with other connective tissue diseases (SLE, SSc, MCTD). Statin-associated IMNM (anti-HMGCR) and anti-SRP antibody-positive IMNM are classified separately. Onset after viral infection (HIV, HTLV-1) reported. |
| 3. Genetics | Polygenic. HLA-DRB1*0301 (DR3), HLA-DRB1*0501 (DR5), and HLA-DQA1*0501 associated with PM susceptibility. Strong association of HLA-DRB1*0301 with anti-Jo-1 antibody-positive PM-ILD. PTPN22, IRF5, and STAT4 polymorphisms contribute to autoimmune mechanisms. In overlap syndromes (PM+SSc, PM+SLE), the genetic background of the respective disease is shared. |
| 4. General epidemiology | Of an adult IIM incidence of about 10~20 per million per year, PM accounts for about 30~40%. Prevalence about 5~15 per 100,000. Female:male = about 2:1. Onset concentrated in the 40s~60s. Pediatric PM very rare. Actual proportion of PM decreased by reclassification of IMNM and antisynthetase syndrome. Korean special copayment reduction V137. |
| 5. Pathophysiology | CD8+ cytotoxic T cells directly infiltrate MHC I-expressing muscle fibers, causing perforin/granzyme B-mediated muscle fiber necrosis. Macrophage infiltration and secretion of IL-1β, TNF-α, and IFN-γ sustain inflammation. Antigen presentation pathway: MHC I overexpression in muscle fibers → TCR recognition by CD8+ T cells → synapse formation → perforin-granzyme secretion. Vascular injury less than in DM, but some MAC deposition also observed. |
| 6. Symptoms | Symmetric proximal muscle weakness (progressing over weeks to months), myalgia and tenderness, dysphagia (pharyngeal muscle involvement). No skin rash (differentiation from DM). Interstitial lung disease (ILD, antisynthetase syndrome), arthralgia and arthritis, Raynaud phenomenon (in overlap syndromes). Fever, fatigue, weight loss (systemic). Myocarditis, pericarditis (rarely). |
| 7. Signs | Proximal muscle weakness (decreased MMT), no skin rash, muscle tenderness, markedly elevated CK, ANA±, possible antisynthetase antibody (anti-Jo-1, etc.) positivity, muscle edema on MRI, myopathic pattern on EMG, muscle biopsy: endomysial CD8+ T cell infiltration of muscle fibers, muscle fiber necrosis and regeneration, MHC I overexpression in muscle fibers. |
| 8. Screening | No general population screening. With proximal muscle weakness + CK elevation: muscle enzymes (CK, LDH, AST, aldolase), ANA, MSA panel (anti-Jo-1, anti-SRP, anti-HMGCR, antisynthetase panel), thyroid function, vitamin D and B12, serum creatinine. Then confirmation approached with MRI (T2 STIR), EMG, and muscle biopsy. ILD screening: pulmonary function and chest HRCT. |
| 9. Diagnosis | In the 2017 EULAR/ACR criteria, PM has no skin-specific items and relies on a diagnosis of exclusion. Muscle biopsy is essential: endomysial CD8+ T cell infiltrate of muscle fibers, MHC I overexpression in muscle fibers, necrotic and regenerating fibers, little vascular injury (difference from DM). MSA/MAA panel to differentiate antisynthetase syndrome, IMNM (anti-HMGCR, anti-SRP), and overlap syndromes. Differentiation from inclusion body myositis (IBM) essential (especially slowly progressive cases in men aged 50 and older). |
| 10. Treatment | Start with high-dose corticosteroids (1mg/kg/day). Steroid-sparing agents: MTX, AZA, MMF. Severe or refractory: IVIG (2g/kg/cycle), rituximab, cyclophosphamide (with ILD). Antisynthetase syndrome ILD: MMF or AZA + steroids; rituximab effective for refractory ILD. IMNM (anti-HMGCR): statin discontinuation + steroids ± MTX; high-dose IVIG effective. Inclusion body myositis (IBM): limited effect of immunosuppressive treatment. |
| 11. Prognosis | 5-year survival about 80~90%. Main causes of death: ILD progression (antisynthetase syndrome), infection, cardiac involvement. Anti-Jo-1-positive PM has high ILD risk but relatively good treatment response. IMNM: the statin-induced type partly improves spontaneously after discontinuation; the anti-HMGCR type requires long-term immunosuppression. Inclusion body myositis (IBM): poor response to immunosuppression, progressive disability in most. With coexisting overlap syndromes, the prognosis of the respective disease has an influence. |
| 12. Prevention | No primary prevention. Secondary and tertiary prevention: early diagnosis and treatment, regular ILD monitoring (pulmonary function, HRCT), early recognition of statin-related muscle symptoms (immediate reporting of CK elevation or muscle weakness while taking statins), infection prevention (up-to-date vaccinations, caution with live vaccines), prevention of steroid complications (osteoporosis, blood glucose, lipids), physical therapy and rehabilitation, regular evaluation for overlapping connective tissue diseases. |
| 13. References | Lundberg IE et al. 2017 EULAR/ACR classification criteria for IIM. Ann Rheum Dis. 2017 … and 9 other papers |
Historical descriptions of Polymyositis (PM) began from a root shared with dermatomyositis. In 1863, Ernst Leberecht Wagner of Germany reported a case accompanied by muscle inflammation, and for decades afterward dermatomyositis with skin rash and cases of muscle inflammation without skin lesions were grouped together and described under the categories of 'polymyositis' or 'dermatomyositis'. In the late 19th~early 20th centuries, several European clinicians reported adult inflammatory muscle diseases characterized mainly by muscle weakness and muscle tenderness, and in 1916 Steinert et al. began to describe polymyositis, as a syndrome of multiple muscle inflammation without skin involvement, separately from dermatomyositis.
After the introduction of corticosteroids in the 1940s, as it was clinically confirmed that polymyositis is an autoimmune disease responsive to immunosuppressive treatment, the identity of polymyositis as an independent clinical subtype began to be established. The classification criteria published by Bohan and Peter in 1975 defined polymyositis as meeting a certain number of four items—proximal muscle weakness, elevated muscle enzymes, electromyographic abnormalities, and muscle biopsy abnormalities—in the absence of skin findings, and were used as the standard for clinical research for decades afterward.
However, since the 2000s, with the discovery of myositis-specific antibodies (MSA) and deepening histopathological research, it was revealed that many patients previously classified as 'polymyositis' actually had immune-mediated necrotizing myopathy (IMNM), antisynthetase syndrome (ASS), or inclusion body myositis (IBM), and the scope of 'true polymyositis' began to be redefined. In particular, after 2004, IMNM associated with anti-HMGCR antibodies and anti-SRP antibodies was separated as a distinct subtype, and in the 2017 EULAR/ACR classification criteria polymyositis remained a diagnosis of exclusion because it has no skin-specific items. In 2022, the ENMC (European Neuromuscular Centre), in its updated IIM classification, separately classified antibody-positive antisynthetase syndrome, anti-SRP/anti-HMGCR-positive IMNM, anti-MBJ-positive PM, and others, so the concept of true 'pure polymyositis' is tending to narrow further. In Korea, clinical registry studies and development of treatment guidelines for polymyositis and dermatomyositis are being carried out, centered on the Korean College of Rheumatology, and polymyositis in Korea is managed as a rare disease under special copayment reduction V137 (polymyositis-dermatomyositis group).
Recently, in clinical practice, cases in which patients diagnosed with polymyositis are reclassified as IMNM or antisynthetase syndrome through appropriate testing are increasing, so systematic performance of MSA panel testing and muscle biopsy is becoming even more important when diagnosing polymyositis. This is because treatment response, organ involvement (ILD risk), and prognosis differ by subtype.
Polymyositis is understood as an autoimmune inflammatory myopathy whose core mechanism is direct attack on muscle fibers by CD8+ cytotoxic T cells. As a multifactorial disease, genetic predisposition, immune dysregulation, and environmental factors are involved in combination. Recently, as a large part of what was previously classified as 'polymyositis' has been reclassified as IMNM or antisynthetase syndrome, the immunopathogenesis of 'pure polymyositis' is being elucidated more precisely.
CD8+ T cell-mediated direct attack on muscle fibers: the key pathological finding on muscle biopsy in polymyositis is infiltration of non-necrotic muscle fibers by CD8+ cytotoxic T cells (CTL) within the endomysium. These CD8+ T cells recognize muscle fibers overexpressing MHC I molecules as self-antigen, form an immunological synapse, and induce muscle fiber apoptosis and necrosis through the perforin/granzyme B pathway. This suggests that polymyositis is a cell-mediated autoimmune disease dependent on MHC I antigen presentation, and means that MHC I expression itself is an essential element of pathogenic self-antigen presentation. Normal muscle fibers express almost no MHC I, but in the muscle fibers of patients with polymyositis, MHC I is extensively overexpressed.
Myositis-specific antibodies (MSA) and pathogenesis: myositis-specific antibodies are also detected in polymyositis. The most important are anti-synthetase antibodies; in particular, the anti-Jo-1 antibody (anti-histidyl-tRNA synthetase) is the most common MSA in both polymyositis and dermatomyositis (about 20% of adult IIM). Anti-Jo-1-positive polymyositis is a clinical subtype called 'antisynthetase syndrome', characterized by ILD, arthritis, Raynaud phenomenon, mechanic's hands, and fever. Patients positive for anti-SRP antibodies and anti-HMGCR antibodies are now classified as IMNM, and separate treatment strategies are applied.
Environmental factors: viral infection is proposed as an environmental trigger of polymyositis. HIV and HTLV-1 (Human T-cell Lymphotropic Virus type 1) are known to directly cause polymyositis-like inflammatory myopathy, in which case invasion of muscle fibers by the virus itself and the immune response to viral antigens are involved in the pathogenesis. Polymyositis-like syndromes have been reported after coxsackievirus, influenza virus, and parvovirus B19 infection. A mechanism has been proposed whereby cross-reactive immune responses between viral antigens and muscle self-antigens through molecular mimicry cause autoimmune myositis.
Association with overlapping connective tissue diseases: polymyositis commonly overlaps with other connective tissue diseases such as systemic sclerosis (SSc), systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD), and Sjögren syndrome, in which case it is termed an 'overlap syndrome'. In overlap syndromes, the immune mechanisms of both diseases operate in combination, and polymyositis occurs together with anti-U1 RNP antibodies (MCTD), anti-Scl-70 and anti-centromere antibodies (SSc), and anti-Ro/SSA and anti-La/SSB antibodies (Sjögren, SLE). Polymyositis in overlap syndromes may respond differently to steroid treatment than isolated polymyositis.
Polymyositis (PM) shows a complex polygenic inheritance pattern and, while sharing some genetic risk factors with dermatomyositis, has subtype-specific HLA associations. Genotype associations by myositis-specific antibody are important for understanding clinical subtypes.
HLA association: HLA-DRB1*0301 (DR3) is reported in several ethnic groups as the strongest susceptibility factor for anti-Jo-1 antibody-positive PM (antisynthetase syndrome) and for polymyositis overall. HLA-DRB1*0501 (DR5) is also associated with increased risk in some polymyositis cohorts. HLA-DQA1*0501 is reported as a susceptibility allele in polymyositis as well as dermatomyositis. In anti-SRP antibody-positive IMNM, an association with HLA-DR5 (DRB1*11:01) is reported. In anti-HMGCR antibody-positive IMNM, there are study results showing associations with HLA-DRB1*11:01 and HLA-DQA1*01:03.
Non-HLA genes: IRF5 (rs2004640, rs10954213, etc.): contributes to overactivation of type I interferon signaling and is reported as a susceptibility factor across autoimmune myositis. STAT4 polymorphisms: involved in IFN-γ responsiveness and regulation of the T cell activation threshold. PTPN22 (rs2476601, W620R variant): lowers the T cell signaling threshold and is associated with increased risk of many autoimmune diseases including polymyositis. TNFAIP3 (A20): controls the inflammatory response through NF-κB regulation, and A20 loss-of-function variants contribute to persistence of autoimmune inflammation.
Genetics of antisynthetase syndrome: in patients positive for anti-Jo-1 antibodies (and other antisynthetase antibodies, anti-PL-7, anti-PL-12, anti-EJ, anti-OJ, anti-KS), a strong association with HLA-DR3 (DRB1*0301) and DQA1*0501 has been established. Immune responses to different synthetase antigens (each aminoacyl-tRNA synthetase) tend to share the same HLA genotype, suggesting that this HLA genotype constitutes a common pathway for the development of antisynthetase autoimmune responses.
Genetic characteristics of IMNM: anti-HMGCR (HMG-CoA reductase) antibody-positive IMNM is characterized by statin exposure, age (more common in the elderly), and association with HLA-DRB1*11:01. Anti-SRP antibody-positive IMNM is associated with more severe muscle involvement and with HLA-DR5. These two IMNM subtypes are currently tending to be treated as separate diagnostic categories rather than M33.2 (polymyositis), but in Korean clinical practice they are still managed within the same special copayment reduction group (V137).
Polymyositis is a major subtype of idiopathic inflammatory myopathy with onset in adults. However, as advances in myositis-specific antibodies (MSA) and histopathology have led to a considerable portion of previous polymyositis diagnoses being reclassified into other subtypes, the actual epidemiological figures for 'pure polymyositis' need to be re-estimated.
Incidence and prevalence: the annual incidence of idiopathic inflammatory myopathy (IIM) overall is about 10~20 per million population, of which polymyositis has traditionally been reported to account for about 30~40%. However, recent studies report that when MSA panel testing and systematic muscle biopsy are performed, a considerable number of patients previously classified as polymyositis (30~50% in some studies) are reclassified as IMNM, antisynthetase syndrome, inclusion body myositis, or overlap syndrome. Therefore, the prevalence of true polymyositis is re-estimated at about 5~10 per 100,000 population. Pediatric polymyositis is very rare, less than about 10% of idiopathic pediatric IIM.
Sex and age distribution: the female-to-male ratio is about 2:1, and the highest incidence is in adults in their 40s~60s. Onset of polymyositis before age 18 is very rare, so adult onset is overwhelming. There are reports that the frequency of association with malignancy is relatively high in male polymyositis, but the risk of tumor association is lower than in dermatomyositis. In antisynthetase syndrome (PM-ILD), female predominance is clear and onset is centered in the 40s.
Racial and ethnic differences: a tendency toward higher incidence and a more severe course in Black and Hispanic adults than in White adults has been reported. In patients of Asian descent, the frequency of anti-MDA5-positive DM is high, whereas the frequency of antisynthetase syndrome is similar to that in the West. Anti-HMGCR-positive IMNM is more frequent in statin-using populations (mainly elderly, high cardiovascular risk groups), and its incidence is increasing with population aging.
Epidemiology in Korea: the combined annual incidence of polymyositis and dermatomyositis in Korea is estimated at about 0.5~1 per 100,000 population, and studies based on health insurance claims data confirm that women and the middle-aged are the main affected groups. In Korea, polymyositis with antisynthetase syndrome-related ILD is an important clinical subtype, and diagnostic awareness of statin-related anti-HMGCR-positive IMNM is increasing. Polymyositis is registered and managed under special copayment reduction V137 (polymyositis-dermatomyositis group).
The pathophysiology of polymyositis centers on direct infiltration and destruction of muscle fibers by CD8+ cytotoxic T cells (CTL), a characteristic unique to polymyositis that distinguishes it from the vasculopathy-centered mechanism of dermatomyositis.
CD8+ T cell-mediated direct attack on muscle fibers: on muscle biopsy in polymyositis, CD8+ cytotoxic T cells are observed infiltrating non-necrotic muscle fibers within the endomysium. This process proceeds as follows. ① MHC I overexpression in muscle fibers: normally muscle fibers express almost no MHC I, but with autoimmune activation or viral infection stimuli, muscle fibers begin to overexpress MHC I. ② TCR recognition by CD8+ T cells: autoreactive CD8+ T cells recognize the MHC I-self-antigen complex on the muscle fiber surface with their TCR and form an immunological synapse on the muscle fiber surface. ③ Muscle fiber apoptosis via the perforin-granzyme B pathway: CD8+ CTLs secrete perforin to form pores in the muscle fiber membrane, and granzyme B enters, activating caspases → inducing apoptosis. ④ Muscle fiber necrosis and persistent inflammation: muscle fiber antigens are released from necrotic muscle fibers, further antigen presentation by dendritic cells and macrophages occurs, and inflammation becomes chronic.
Macrophage infiltration and cytokines: activated macrophages (M1 phenotype) within the endomysium also play a major role in the pathology of polymyositis. IL-1β, TNF-α, IL-6, and IFN-γ secreted by macrophages contribute to muscle fiber damage and induction of MHC I expression. IFN-γ strongly upregulates MHC I expression in muscle fibers, forming a feedback loop that amplifies CD8+ T cell recognition and attack. The role of type I IFN (IFN-α/β) is less prominent in polymyositis than in dermatomyositis, but an interferon signature is observed in some patients.
Pathogenesis of antisynthetase syndrome: aminoacyl-tRNA synthetases, the target antigens of antisynthetase antibodies (anti-Jo-1, etc.), are widely expressed in muscle cells, vascular endothelial cells, and lung epithelial cells. It has been proposed that antisynthetase antibodies themselves play a direct pathogenic role targeting muscle fibers and lung epithelial cells, or cause multisystem autoimmunity through the formation of antigen-antibody immune complexes. It is understood that histidyl-tRNA synthetase (Jo-1 antigen) moves to the cell surface during apoptosis and is recognized by immune cells, and that the antisynthetase autoimmune response is initiated through similarity to viral proteins by molecular mimicry. Because antisynthetase antigens are abundantly expressed in lung tissue, this is offered as the explanation for why ILD is prominent in antisynthetase syndrome.
Mechanism of IMNM: in anti-HMGCR (HMG-CoA reductase)-positive IMNM, when statins increase HMGCR expression in muscle fibers, the immune system recognizes it as an exogenous antigen and produces anti-HMGCR autoantibodies. These antibodies bind to muscle fiber HMGCR, causing complement activation and immune-mediated muscle fiber damage. If autoantibody production persists even after statins are discontinued, muscle fiber damage continues. In anti-SRP antibody-positive IMNM, antibodies against the signal recognition particle (SRP) are proposed to play a direct pathogenic role.
The clinical symptoms of polymyositis center on proximal muscle weakness, and the absence of skin rash is the main point of differentiation from dermatomyositis. In antisynthetase syndrome, symptoms of multisystem involvement including the lungs, joints, and skin (mechanic's hands) are added.
Muscle symptoms: symmetric proximal muscle weakness is the core symptom of polymyositis, mainly involving the muscles of the shoulder girdle and pelvic girdle. Symptoms progress gradually over weeks to months and present as difficulty climbing stairs, difficulty rising from a chair, difficulty raising the arms above the head, and difficulty washing the face or combing hair. Neck flexion strength may also decrease, and head drop appears. When the pharyngeal muscles are involved, dysphagia and the risk of food aspiration increase. Involvement of the esophageal muscles (upper esophageal smooth muscle) causes dysphagia and reflux. Respiratory muscle involvement is rare but can lead to respiratory failure in severe cases. Myalgia and muscle tenderness accompany in about 50~60%.
Absence of skin symptoms: the defining characteristic of polymyositis is the absence of the dermatomyositis-specific skin findings (heliotrope rash, Gottron papules). However, in antisynthetase syndrome, mechanic's hands (hyperkeratosis and fissuring of the lateral fingers and palms) may appear, which is a finding different from the heliotrope rash or Gottron papules of dermatomyositis.
Interstitial lung disease (ILD): ILD is the most important organ complication in antisynthetase syndrome-associated polymyositis. ILD develops in about 60~70% of anti-Jo-1 antibody-positive patients. The rate of ILD is also high with positivity for other antisynthetase antibodies (anti-PL-7, anti-PL-12, anti-KS). Symptoms appear as exertional dyspnea, cough, fever, and decreased oxygen saturation, and it may progress slowly or worsen acutely.
Joint symptoms: arthralgia and non-erosive polyarthritis accompany about 50~70% of antisynthetase syndrome. The joints of the hands, wrists, and knees are mainly involved. Raynaud phenomenon is also observed in about 20~40%.
Systemic symptoms: fever, fatigue, weight loss, and anorexia may appear early. Cardiac involvement (myocarditis, arrhythmia, pericarditis) is rare but can occur in severe polymyositis. In IMNM (anti-HMGCR), very marked CK elevation (10,000~100,000 IU/L or more) and rapidly progressive muscle weakness are characteristic.
The physical signs of polymyositis center on proximal weakness on muscle strength testing and the absence of skin rash, and in antisynthetase syndrome, pulmonary and joint signs are added.
Muscle strength testing findings: standardized manual muscle testing (MMT-8) evaluates the strength of shoulder abduction, elbow flexion and extension, wrist flexion, hip flexion, knee extension, and ankle dorsiflexion. Proximal strength (shoulder and pelvic girdles) is markedly more reduced than distal strength. When distal weakness is prominent, inclusion body myositis (IBM) or muscular dystrophy must be differentiated. Weakness of neck flexion is confirmed by the head-lift test in the supine position. Tenderness is found on palpation of muscles with myalgia.
No skin findings: the absence of dermatomyositis-specific skin findings such as heliotrope rash, Gottron papules, and the V-sign is an important requirement for the diagnosis of polymyositis. In antisynthetase syndrome, mechanic's hands (hyperkeratosis and fissuring of the lateral fingers) may appear. Raynaud phenomenon (digital vasospasm, white-blue-red color changes) appears in some patients.
Pulmonary signs: with coexisting ILD, bibasilar fine crackles are heard on auscultation. Pulmonary function tests show a restrictive pattern (decreased FVC, DLCO). Decreased oxygen saturation (at rest or during the 6-minute walk test) is a marker of ILD progression.
Main laboratory findings: CK elevation is the most important laboratory finding. Especially in IMNM, CK can be extremely elevated to 10,000 IU/L or more (in typical polymyositis, CK about 1,000~10,000 IU/L). LDH, AST, ALT, and aldolase are also elevated. ANA: positive at low titer in about 40~60%. Anti-Jo-1 antibody (and other antisynthetase antibodies): confirms antisynthetase syndrome. Anti-SRP and anti-HMGCR antibodies: confirm IMNM. ESR and CRP elevated. Electromyography (EMG): myopathic pattern (short-duration, low-amplitude motor unit potentials, increased spontaneous activity). Muscle MRI (T2 STIR): widespread intramuscular edema (high signal intensity); fascial inflammation may be less than in DM.
Muscle biopsy findings: findings specific to polymyositis: ① endomysial CD8+ T cell and macrophage infiltration (within or around non-necrotic muscle fibers). ② MHC I overexpression in muscle fibers (widespread). ③ Muscle fiber necrosis and regenerating fibers. ④ The vascular deposition characteristic of DM (C5b-9, MAC) is markedly less in polymyositis. ⑤ Differentiation from inclusion body myositis: PM lacks rimmed vacuoles, inclusion bodies, and filamentous inclusions (TDP-43 immunohistochemistry).
General population screening for polymyositis is not recommended. However, when an adult has proximal muscle weakness and CK elevation, it is important to systematically evaluate inflammatory myopathies including polymyositis, and classification into clinical subtypes through MSA panel testing is key.
Criteria for clinical suspicion: inflammatory myopathy including polymyositis is suspected when one or more of the following findings are present. ① Unexplained proximal symmetric muscle weakness (progressing over weeks to months), ② marked CK elevation (3 times or more the upper limit of normal), ③ the combination of fever and weight loss with muscle weakness. In adults without skin findings whose main complaint is proximal muscle weakness, differentiation of polymyositis is considered first.
Basic blood tests: CK, LDH, AST, ALT, aldolase (markers of muscle damage), CBC (markers of overlapping connective tissue diseases such as cytopenias), liver function, renal function, and electrolytes (to differentiate secondary causes of muscle enzyme elevation), thyroid function tests (to differentiate CK elevation due to hypothyroidism), vitamin D and B12 (to differentiate muscle weakness due to deficiency), CRP and ESR (systemic inflammation).
Autoantibody tests: ANA (screening). MSA panel: anti-Jo-1, anti-PL-7, anti-PL-12, anti-EJ, anti-OJ, anti-KS (antisynthetase panel), anti-SRP, anti-HMGCR (to differentiate IMNM), anti-Mi-2, anti-MDA5, anti-TIF1γ (to differentiate dermatomyositis), anti-NXP2, anti-SAE1. Anti-U1 RNP (to differentiate MCTD), anti-Scl-70 and anti-centromere (to differentiate SSc). These tests not only confirm the diagnosis but directly affect ILD risk assessment, determination of tumor association, and formulation of treatment strategy.
Advanced tests: muscle MRI (T2 STIR): identification of sites of active muscle inflammation and selection of the biopsy site. EMG: confirmation of a myopathic pattern, differentiation from neuropathy. Muscle biopsy: essential for confirmation; PM confirmed by CD8+ T cell infiltration, necrosis and regeneration, and MHC I expression; differentiation of DM, IBM, and IMNM. Pulmonary function tests (FVC, DLCO) and chest HRCT: evaluation of coexisting ILD, especially important in anti-Jo-1-positive patients. Echocardiography: evaluation of myocardial involvement. Cancer screening: basic tumor screening with CT, endoscopy, etc. in adult polymyositis (especially older men) (risk lower than in dermatomyositis, but considered in overlap syndromes).
The diagnosis of polymyositis involves an integrated evaluation of characteristic clinical findings, serology, imaging, electrophysiology, and histopathology, and differentiation from dermatomyositis, inclusion body myositis (IBM), IMNM, antisynthetase syndrome, and overlapping connective tissue diseases is especially key. Because the 2017 EULAR/ACR criteria have no clinical items specific to polymyositis, the diagnosis tends to be made by exclusion, so muscle biopsy is essential.
Position of PM in the 2017 EULAR/ACR classification criteria: the 2017 criteria distinguish DM through skin-specific items and, after excluding IBM through inclusion bodies, classify the remaining inflammatory myopathies as polymyositis or other IIM. Items contributing points in adult PM: age of onset ≥40 years (+1.4 points), proximal muscle weakness (+0.7 points), CK elevation (+1.3 points), arthralgia (+0.7 points), cough (+0.7 points), muscle MRI (+1.2 points). Muscle biopsy results: endomysial CD8+ infiltrate of muscle fibers (+3.1 points), MHC I overexpression in muscle fibers (+2.0 points). PM classification is strengthened only when all skin-specific items are negative.
Muscle biopsy — the core of diagnosis: muscle biopsy is essential for confirming polymyositis. It is taken from a muscle with high T2 STIR signal under MRI guidance. Findings confirming polymyositis: ① endomysial CD8+ T cell infiltration (confirmed by immunohistochemistry), ② widespread MHC I overexpression in muscle fibers (immunohistochemistry), ③ muscle fiber necrosis and regeneration (H&E staining), ④ no rimmed vacuoles (excluding IBM), ⑤ no marked vascular C5b-9 (MAC) deposition (distinguishing from DM). To differentiate inclusion body myositis (IBM), TDP-43 immunohistochemistry and electron microscopy (to confirm filamentous inclusions) may be needed.
Differential diagnosis: inclusion body myositis (IBM): men aged 50 and older, gradual progression without delay, mixed distal (especially quadriceps, finger flexors) and proximal involvement, dysphagia, rimmed vacuoles and TDP-43 inclusions on biopsy, poor response to immunosuppressants. IMNM: extremely high CK (>10,000 IU/L), anti-HMGCR (statin-associated) or anti-SRP positivity, numerous necrotic and regenerating muscle fibers on biopsy, little inflammatory infiltration. Dermatomyositis (DM): presence of heliotrope rash and Gottron papules, perivascular inflammation and C5b-9 deposition on biopsy. Antisynthetase syndrome: antisynthetase antibody positivity, coexisting ILD, arthritis, mechanic's hands, presenting as either PM or DM. Overlap syndromes: findings of other connective tissue diseases (SSc, SLE, MCTD). Hypothyroidism, drug-induced myopathy, and metabolic myopathy are also differential diagnoses.
Clinical significance of the MSA panel: anti-Jo-1 positive: consider reclassification as antisynthetase syndrome; check for ILD, arthritis, and mechanic's hands. Anti-SRP or anti-HMGCR positive: reclassify as IMNM; check for statin exposure. MSA negative: consider the possibility of pure polymyositis, overlap syndrome, or IBM.
The goals of treatment of polymyositis are recovery of muscle strength, stabilization of ILD, prevention of complications, and improvement of quality of life. Treatment is individualized according to clinical subtype (pure PM, antisynthetase syndrome, IMNM), severity, and organ involvement.
Corticosteroids — first-line treatment: treatment is started with oral prednisolone 1mg/kg/day (maximum 60~80mg/day), and in severe cases (severe muscle weakness, dysphagia, acute ILD, cardiac involvement), intravenous methylprednisolone pulses (500~1,000mg/day × 3 days) are used first. After 4~6 weeks, gradual tapering begins according to the clinical response (muscle strength, CK). Rather than steroids alone, early combination with steroid-sparing immunosuppressants is recommended to prevent relapse and reduce steroid adverse effects.
Steroid-sparing immunosuppressants: methotrexate (MTX, 10~20mg/week): effective for muscle and joint symptoms; caution with coexisting ILD due to concern about pulmonary toxicity. Azathioprine (AZA, 1.5~2.5mg/kg/day): standard for maintenance treatment; can be used even with coexisting ILD. Mycophenolate mofetil (MMF, 2~3g/day): preferred in antisynthetase syndrome with ILD; effective for maintenance treatment. Cyclosporine (3~5mg/kg/day): combined with steroids in PM with ILD (especially antisynthetase syndrome). Tacrolimus: an alternative to cyclosporine, used with coexisting ILD.
Intravenous immunoglobulin (IVIG): IVIG (2g/kg/cycle) is effective for the muscle symptoms of polymyositis and is added in steroid-refractory cases or when steroid-related adverse effects are a concern. In IMNM, high-dose IVIG is particularly effective and is used as part of standard treatment in some anti-HMGCR-positive IMNM.
Biologic agents: rituximab: efficacy reported in refractory polymyositis (especially antisynthetase syndrome, anti-SRP-positive IMNM) through reduction of autoantibodies by B cell depletion. In the RIM clinical trial, rituximab showed improvement in muscle strength and clinical measures in adult refractory IIM. Abatacept (CTLA4-Ig): efficacy demonstrated in a phase 3 clinical trial in adult IIM through a mechanism of blocking T cell activation costimulation. JAK inhibitors: effective in small studies in antisynthetase syndrome-related ILD. Cyclophosphamide (CTX): given intravenously in rapidly progressive ILD.
Treatment of antisynthetase syndrome ILD: MMF or AZA + steroids are the first choice. If refractory, rituximab, cyclosporine, or tacrolimus is added. In acute exacerbation, intravenous CTX + steroids in combination. Lung transplantation is considered in some cases of end-stage ILD.
Treatment of IMNM: in statin-induced anti-HMGCR-positive IMNM, immediate statin discontinuation is essential, but if autoantibodies persist, steroids + MTX or AZA are combined. High-dose IVIG is particularly effective. Anti-SRP-positive IMNM is more severe and refractory to steroids alone, often requiring combination with rituximab and high-dose IVIG.
The prognosis of polymyositis differs considerably depending on clinical subtype, MSA type, organ involvement, and whether treatment was started early. Overall, the 5-year survival rate is about 80~90%, but the prognosis may be poor in antisynthetase syndrome with ILD or anti-SRP-positive IMNM.
Types of disease course: ① Monocyclic (about 20~30%): complete remission achieved after treatment, no relapse. ② Polycyclic (about 30~40%): repeated remission and relapse, long-term immunosuppression needed. ③ Chronic persistent (about 30~40%): chronic persistent disease activity, especially in antisynthetase syndrome-related ILD or overlap syndromes. Inclusion body myositis (IBM): refractory to immunosuppression, continuously progressive, the poorest.
Prognostic determinants: poor prognosis: anti-Jo-1 positivity + severe ILD (fibrotic pattern), anti-SRP-positive IMNM (extreme CK elevation, rapid worsening of muscle strength), dysphagia and aspiration risk, cardiac involvement, diagnostic delay, elderly onset, treatment refractoriness. Good prognosis: early diagnosis and treatment, MSA negativity or anti-Mi-2 positivity (when close to the DM phenotype), good steroid response, polymyositis without ILD, improvement after statin discontinuation in anti-HMGCR-positive IMNM.
Prognosis of interstitial lung disease (ILD): the prognosis of antisynthetase syndrome-related ILD differs by ILD subtype. Nonspecific interstitial pneumonia (NSIP) and organizing pneumonia (OP) patterns have a relatively good treatment response. The usual interstitial pneumonia (UIP) pattern has a strong tendency toward progressive fibrosis and a poor prognosis. In anti-KS antibody-positive patients, there may be ILD only without muscle symptoms. Continuous progression of ILD is the main cause of polymyositis-related death.
Prognosis of inclusion body myositis (IBM): IBM is the IIM subtype with the poorest prognosis, not responding to immunosuppressive treatment, and continuous progression of muscle weakness leads to loss of ambulation within an average of 10~15 years. Because IBM can be clinically confused with polymyositis, IBM should be re-evaluated in patients with polymyositis who do not respond to treatment.
Long-term complications: steroid-related complications (osteoporosis, diabetes, hypertension, cataracts, avascular osteonecrosis), respiratory impairment due to chronic ILD, joint contractures, persistent muscle atrophy, swallowing disorders, and cognitive decline (rarely) impair long-term quality of life. Because infection (including pneumonia) is a major cause of death in patients with polymyositis, infection surveillance and prevention during immunosuppressive treatment are important.
Primary prevention of polymyositis is currently not possible. Secondary and tertiary prevention strategies focus on early diagnosis, prevention of complications, minimization of steroid-related adverse effects, and regular monitoring.
Early diagnosis and initiation of treatment: in polymyositis, diagnostic delay leads to accumulation of muscle damage, ILD progression, decline in swallowing function, and joint contractures. In adults with unexplained proximal muscle weakness and CK elevation, prompt referral to rheumatology or neurology is important. In particular, when muscle weakness or CK elevation occurs while taking statins, the possibility of immune-mediated necrotizing myopathy (IMNM) is considered, and statins are discontinued immediately while anti-HMGCR and anti-SRP antibody testing is performed.
Regular ILD monitoring: in antisynthetase antibody-positive polymyositis patients, ILD progression is detected early through pulmonary function tests (FVC, DLCO) at 6~12-month intervals and chest HRCT once a year or when symptoms change. When FVC decreases by > 10% or new respiratory symptoms develop, immediate intensification of immunosuppressive treatment is considered. Acute exacerbation can progress rapidly to respiratory failure and requires inpatient treatment.
Infection prevention: in polymyositis patients on immunosuppressive treatment, inactivated vaccines such as influenza, pneumococcal, and hepatitis B are kept up to date. Live vaccines (varicella, MMR, etc.) are contraindicated in moderate or greater immunosuppression. Pneumocystis pneumonia (PCP) prevention: with high-dose steroids + immunosuppressant combination, prophylactic TMP-SMX (trimethoprim-sulfamethoxazole) is considered. After screening for latent tuberculosis infection (IGRA or tuberculin skin test), isoniazid preventive treatment is given if positive (the possibility of drug-induced lupus is low but monitoring is needed).
Prevention of steroid-related complications: osteoporosis is prevented through calcium (1,000~1,200mg/day), vitamin D (600~1,000 IU/day), weight-bearing exercise, and a healthy diet. In patients on long-term steroids (≥3 months), DEXA bone density testing and bisphosphonate treatment are considered. Blood glucose, blood pressure, and lipids are monitored regularly to manage steroid-induced metabolic complications (diabetes, hypertension, dyslipidemia) early.
Physical therapy and rehabilitation: in the acute phase, passive joint exercises and low-intensity aerobic exercise within a range that does not cause fatigue are performed, and in the remission phase, gradual active strength training is introduced. In patients with dysphagia, swallowing rehabilitation and dietary modification in collaboration with a speech therapist are key to preventing aspiration pneumonia. In IBM patients, because immunosuppressive treatment is ineffective, rehabilitation for preserving function and the use of assistive devices (ankle-foot orthosis, special chairs, etc.) are the center of long-term management.
Education on preventing statin-related IMNM: all patients taking statins are educated to report immediately to their physician if muscle weakness, CK elevation, or brown urine (myoglobinuria) occurs. They are guided to understand the range of statin-related muscle adverse effects (myalgia, myopathy, rhabdomyolysis, immune-mediated necrotizing myopathy) and to decide after consulting the medical team rather than stopping on their own.
Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76(12):1955-1964. DOI: 10.1136/annrheumdis-2017-211468. PMID: 28595184.
Dalakas MC. Inflammatory muscle diseases. N Engl J Med. 2015;372(18):1734-1747. DOI: 10.1056/NEJMra1402225. PMID: 25923553.
Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis (RIM study). Arthritis Rheum. 2013;65(2):314-324. DOI: 10.1002/art.37754. PMID: 23124935.
Mammen AL. Statin-associated autoimmune myopathy. N Engl J Med. 2016;374(7):664-669. DOI: 10.1056/NEJMra1515161. PMID: 26886523.
Aggarwal R, Cassidy E, Fertig N, et al. Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis. 2014;73(1):227-232. DOI: 10.1136/annrheumdis-2012-203141. PMID: 23376703.
Benveniste O, Guiguet M, Freebody J, et al. Long-term observational study of sporadic inclusion body myositis. Brain. 2011;134(Pt 11):3176-3184. DOI: 10.1093/brain/awr213. PMID: 21954082.
Nishino I, Suzuki N, Nonaka I. Anti-signal recognition particle myopathy: case reports and review. Muscle Nerve. 2007;36(5):719-722. DOI: 10.1002/mus.20846. PMID: 17674357.
Rider LG, Werth VP, Huber AM, et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis. Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S118-S157. DOI: 10.1002/acr.20505. PMID: 22588741.
Allenbach Y, Mammen AL, Benveniste O, Stenzel W. 224th ENMC International Workshop: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies. Neuromuscul Disord. 2018;28(1):87-99. DOI: 10.1016/j.nmd.2017.09.016. PMID: 29292179.
Kim KJ, Park CK, Kim YW, et al. Clinical features and prognosis of Korean patients with polymyositis: a retrospective single center study. Korean J Intern Med. 2018;33(5):929-937. DOI: 10.3904/kjim.2016.275. PMID: 28715199.